The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline ...

Following this month's FDA approval of Eli Lilly’s amyloid-busting antibody Kisunla (donanemab), the Alzheimer’s disease ...

The FDA approved the experimental Alzheimer's drug donanemab. The drug will be sold under the brand name Kisunla.

The U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV ...

GlobalData forecasts that Leqembi and Kisunla could generate global sales of approximately $3.5 billion and $2.0 billion ...

U.S. health officials have approved a new Alzheimer’s drug that can modestly slow the disease. It's only the second drug that ...

The FDA today approved Eli Lilly’s Kisunla™ (donanemab-azbt), a once-monthly treatment for adults with early Alzheimer's ...

The Food and Drug Administration (FDA) has approved Kisunla ™ (donanemab-azbt) for the treatment of Alzheimer disease.

The U.S. Food and Drug Administration (FDA) has approved Eli Lilly‘s antibody therapy donanemab, now Kisunla, for certain ...

Eli Lilly received FDA approval for a drug to help treat Alzheimer's on Tuesday after studies showed it could help slow the ...